Arena jumps on resubmission of NDA for weight-loss drug
This article was originally published in Scrip
Executive Summary
After the markets closed on 3 January, Arena Pharmaceuticals and its partner Eisai revealed they had submitted new data last week to the US FDA to address the agency's October 2010 complete response letter (CRL) rejecting the firms' new drug application (NDA) for their experimental weight loss drug lorcaserin.